Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 1/20 | 0.46 |
| ▸ | CPT1A | P50416 | 1/20 | 0.46 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.37 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3680571 | 0.88 | CPT2 (0.50) | CPT2CPT1ACPT1BCYP2D6GGPS1 | |
| Trifluoroacetic Acid SCHEMBL3680574 | 0.88 | CPT2 (0.50) | CPT2CPT1ACPT1BCYP2D6GGPS1 | |
| SCHEMBL13410041 | 0.87 | CPT2 (0.51) | CPT2CPT1ACPT1BCYP2D6CNR1 | |
| SCHEMBL3682672 | 0.87 | FAAH (0.36) | CPT2CPT1ACPT1B | |
| SCHEMBL13444489 | 0.79 | PPARA (0.48) | CYP2D6GGPS1CNR1CNR2KCNH2 | |
| SCHEMBL3690943 | 0.79 | PPARG (0.49) | CPT2CPT1ACPT1B | |
| SCHEMBL3688863 | 0.78 | NPC1 (0.31) | — | |
| SCHEMBL3681769 | 0.75 | ALDH1A1 (0.43) | — | |
| SCHEMBL3687517 | 0.74 | ACACB (0.35) | CPT2CPT1ACPT1B | |
| SCHEMBL14069946 | 0.74 | CPT2 (0.53) | CPT2CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | claimed |
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.